CoChat

Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey

Open access
Reid Finlayson, Alistair J., Macoubrie, Jane, Huff, Christy, Foster, D.E., Martin, Peter R. · 2022 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index; 2 of the 19 sources its claims cite were checked for support.

Abstract

Background: Over 92 million prescriptions for benzodiazepines are dispensed in the United States annually, yet little is known about the experiences of those taking and discontinuing them. Objective: The aim of this study is to assess the experiences of those taking, tapering, or having discontinued benzodiazepines. Methods: An online survey ( n = 1207) elicited information about benzodiazepine use, including long-term use, tapering, discontinuation, and withdrawal symptoms. Results: Symptoms associated with benzodiazepine use, tapering, and discontinuation were numerous and ranged from symptoms such as anxiety, insomnia, and nervousness to digestive problems, irregular heart rhythms, uncontrollable anger, photosensitivity, balance problems, and others. When asked how benzodiazepine symptoms affected their lives, 82.9% reported work problems, 86.3% had problems with social interactions and friendships, and 88.8% had problems with fun, recreation, and hobbies. Suicidal thoughts or attempted suicide was reported by 54.4%, and 46.8% said benzodiazepines caused lost employment. Most of the respondents for whom benzodiazepines were prescribed (76.2%) stated they had not been informed that benzodiazepines were indicated for short-term use only and that discontinuation might be difficult. About a third (31.5%) reported food allergies and/or seasonal allergies that occurred only after benzodiazepine use. Conclusion: The trajectory of those who taper or discontinue benzodiazepines is unpredictable, and many patients experience a range of protracted and severe symptoms, even years after benzodiazepines were completely discontinued. Greater awareness is needed for both prescribers and patients about the potential for a difficult withdrawal from benzodiazepines.

Overview

CoChat Summary

TL;DR

An Internet survey of 1,207 benzodiazepine users found numerous severe and long-lasting symptoms during use, tapering, and after discontinuation, with substantial life impacts and suicidal thoughts reported. Most respondents said they had not been informed that benzodiazepines were indicated for short-term use only and that discontinuation might be difficult.

Key findings

  • Of 1,207 finishers, 63.2% had discontinued benzodiazepines, 24.4% were tapering, and 11.3% continued on a full dose. Symptoms often persisted for years: low energy 51.6%, nervousness/anxiety/fear 50.2%, sleep disturbances 49.0%, and memory loss 44.2% were reported as lasting years.
  • Life effects were common: 82.9% reported work problems, 86.3% social interaction/friendship problems, and 88.8% problems with fun, recreation, and hobbies; 54.4% reported suicidal thoughts or attempted suicide, and 46.8% said benzodiazepines caused lost employment.
  • Most respondents (76.2%) said their health care providers “definitely did not” tell them benzodiazepines were intended for short-term use and discontinuation might be difficult; 5.6% said they were “probably not” given this information.
  • New conditions after benzodiazepine use included food and/or seasonal allergies in 31.5%, sensitivity to food additives or other chemicals in 41.2%, autoimmune diagnosis after initiation in 18.1% versus 11.5% before, and falls/fractures beginning after starting benzodiazepines in 21.0% versus 5.9% before.

Methods

  • Anonymous online survey with 19 questions covering demographics, benzodiazepine use history, symptoms, and outcomes; recruited as a convenience sample from 16 Internet sites, including benzodiazepine-related websites and 10 Facebook groups, posted three times (October 2018, November 2018, January 2019).
  • Qualtrics was used to allow only one response per IP address; 1,682 individuals started the survey and 1,207 were identified as finishers, though some did not answer every question. Respondents were 71% female, 26% male, and 2% other/prefer not to state; 76.6% lived in the United States.
  • Results were analyzed in SAS by a medical statistician and confirmed by an experienced data scientist using Microsoft SQL server; the article reports compliance with CROSS methodology.

Limitations

  • The paper states there was no control group; recruitment was from social media and online sources dealing with benzodiazepine use and withdrawal, producing a self-selected convenience sample that may not represent all benzodiazepine users.
  • The paper states that multiple-choice symptom lists may have made patients suggestible, may have led to incorrect recall or attribution of symptoms, and that nocebo effects were not accounted for; suicidal thoughts may be underreported even in an anonymous survey.
  • The paper notes that Internet health-information users tend to be younger and online support-group members tend to be in worse health, so results may not be generalizable; the text also makes evident that the cross-sectional survey cannot establish causality or true incidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/20451253221082386

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 0 Not valid · 16 Not checked · 60 Own results and interpretations

40 more claims

Create a free account to see all 78 claims and to verify the 17 references still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 21 references

Cited by

See all 42

Metadata

Authors
Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R.
Affiliations
  • Department of Psychiatry and Behavioral Sciences, Vanderbilt Psychiatric Hospital, Vanderbilt University Medical Center, Suite 3010, 1601 23rd Avenue South, Nashville, TN 37212, USA
  • University of Southern California (US)
  • Benzodiazepine Information Coalition, Midvale, UT, USA
  • Benzodiazepine Action Work Group, Colorado Consortium for Prescription Drug Abuse Prevention, Aurora, CO, USA
  • Vanderbilt University Medical Center (US)
Venue
Therapeutic Advances in Psychopharmacology
Published
2022-01
Volume
12
Pages
20451253221082386-20451253221082386
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W4225985734
Cited by
40
References
21
Citations by year
2026: 12 · 2025: 9 · 2024: 7 · 2023: 10 · 2022: 2
FWCI
4.00
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
benzodiazepines, benzodiazepine tapering, benzodiazepine discontinuation, long-term benzodiazepine use, patient experience, suicidal ideation, employment problems, food allergy, seasonal allergy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. https://app.cochat.ai/papers/10.1177/20451253221082386
The paper
Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022). Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253221082386

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.